Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine

The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Recondo, Gonzalo, de la Vega, Maximo, Galanternik, Fernando, Díaz-Cantón, Enrique, Leone, Bernardo Amadeo, Leone, José Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876844/
https://www.ncbi.nlm.nih.gov/pubmed/27274311
http://dx.doi.org/10.2147/CMAR.S104447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876844/
https://www.ncbi.nlm.nih.gov/pubmed/27274311
http://dx.doi.org/10.2147/CMAR.S104447

Ejemplares similares